<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03104036</url>
  </required_header>
  <id_info>
    <org_study_id>F16-27449A</org_study_id>
    <nct_id>NCT03104036</nct_id>
  </id_info>
  <brief_title>Faecal Bacteriotherapy for Ulcerative Colitis</brief_title>
  <acronym>FACTU</acronym>
  <official_title>Faecal Bacteriotherapy for Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Clinical and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Animal Physiology and Genetics Academy of Science Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute for Clinical and Experimental Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The etiopathogenesis of ulcerative colitis (UC) is not fully understood. One of the theories&#xD;
      of UC pathogenesis represents a pathological response of mucosal immunity to intestinal&#xD;
      microbiota. Potential therapeutic procedure how to affect this fact is the faecal microbiota&#xD;
      transplantation (FMT). Review of the literature on FMT suggests great potential as the&#xD;
      treatment for UC, but two prospective controlled study that has been published yet are&#xD;
      inconsistent.&#xD;
&#xD;
      The first objective of the project is to compare the administration of FMT enema with&#xD;
      mesalazine enema for inducing remission in patients with active left-sided UC in the form of&#xD;
      a prospective, randomized, controlled study. The second objective is to observe changes in&#xD;
      the intestinal microbiota during and after FMT focusing on bacterial DNA sequencing to&#xD;
      identify the bacterial species which are responsible for the effect of the FMT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2017</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">January 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be split into two branches of the study by randomization criteria (gender, imunosupresive therapy). Each branch of the study will have 25-30 patients. The first group will be treated with 4 g mesalazine enema 1x daily for 2 weeks, then every other day until the end of the 6th week. A second group of patients will be applied enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline, the 1st week 5 times, than one time a week until the end of the 6th week.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical remission</measure>
    <time_frame>Week 12</time_frame>
    <description>Mayo score ≤ 2 with no subscore &gt; 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endoscopic remission</measure>
    <time_frame>Week 6 and 12</time_frame>
    <description>Mayo endoscopic score = 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Week 6 and 12</time_frame>
    <description>Decrease of Mayo score ≥ 2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Mesalazine enema</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will be treated with 4 g mesalazine enema 1x daily for 2 weeks, then every other day until the end of the 6th week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Faecal bacterial transplantation enema</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will be applied enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline, the 1st week 5 times, than one time a week until the end of the 6th week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Faecal bacterial transplantation</intervention_name>
    <description>Enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline</description>
    <arm_group_label>Faecal bacterial transplantation enema</arm_group_label>
    <other_name>FMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalazine 4G Enema</intervention_name>
    <description>Standard mesalazine enema</description>
    <arm_group_label>Mesalazine enema</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Left-sided ulcerative colitis &gt; 15cm ongoing more than 3 month&#xD;
&#xD;
          -  Mayo score &lt; 10&#xD;
&#xD;
          -  Endoscopic Mayo score ≥ 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anti-TNF medication in the previous 6 months&#xD;
&#xD;
          -  Cyclosporine in the previous 4 weeks&#xD;
&#xD;
          -  Methotrexate in the previous 2 months&#xD;
&#xD;
          -  Prednisone &gt; 10mg&#xD;
&#xD;
          -  The real risk of colectomy in the near future&#xD;
&#xD;
          -  Positive stool culture (Salmonella, Shigella, Yersinia, Campylobacter, pathogenic E.&#xD;
             coli)&#xD;
&#xD;
          -  CMV infection&#xD;
&#xD;
          -  Pregnancy, breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gastroenterology departement Hospital České Budějovice</name>
      <address>
        <city>Ceske Budejovice</city>
        <state>Jihočeský Kraj</state>
        <zip>370 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum péče o zažívací trakt Vítkovická nemocnice</name>
      <address>
        <city>Ostrava - Vitkovice</city>
        <state>Moravskoslezský Kraj</state>
        <zip>703 84</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second department of internal medicine of University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <state>Olomoucký Kraj</state>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IV. Department of Internal Medicine, General University Hospital in Prague</name>
      <address>
        <city>Prague</city>
        <state>Prague 2</state>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal departement of Thomayer Hospital</name>
      <address>
        <city>Prague</city>
        <state>Prague 4</state>
        <zip>14059</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISCARE</name>
      <address>
        <city>Prague</city>
        <state>Prague 7</state>
        <zip>17004</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>II. Department of Internal Medicine University Hospital Vinohrady</name>
      <address>
        <city>Prague</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of clinical and experimental medicine</name>
      <address>
        <city>Prague</city>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal departement Hospital Na Bulovce</name>
      <address>
        <city>Prague</city>
        <zip>150 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 27, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Clinical and Experimental Medicine</investigator_affiliation>
    <investigator_full_name>Jan Březina</investigator_full_name>
    <investigator_title>MUDr. (principal investigator)</investigator_title>
  </responsible_party>
  <keyword>Feacal bacterial transplantation</keyword>
  <keyword>Left-sided ulcerative colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

